MedTrace Logo

Clinical and Radiographic Success of MTA vs Biodentine

NCT04863222 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 646

Last updated 2025-12-23

No results posted yet for this study

Summary

The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.

Conditions

  • Indirect Pulp Cap
  • Pulpotomy

Interventions

DEVICE

Biodentine

During a patients procedure, one tooth will receive Biodentine instead of MTA.

BIOLOGICAL

mineral trioxide aggregate (MTA)

mineral trioxide aggregate (MTA)

Sponsors & Collaborators

  • Geisinger Clinic

    lead OTHER

Principal Investigators

  • Gayatri Malik, DMD · Geisinger Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-12
Primary Completion
2026-08-01
Completion
2026-12-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04863222 on ClinicalTrials.gov